News and reporting on BRAF biomarkers.
More individuals treated with BRAF- and MEK-targeted drugs were still alive after four years than would be expected with conventional chemo drugs.
In a study, patients with class 3 BRAF mutations were more likely to respond to an anti-EGFR antibody treatment as a first-or second-line therapy.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
While the oncology field moves toward NGS panel testing, the drugmaker has launched a program subsidizing single-gene testing for advanced melanoma patients.
An international team saw an overall survival benefit when using BRAF, MEK, and EGFR inhibitors together in previously treated, BRAF-mutated metastatic colorectal cancer patients.
The successful development of new targeted tissue-agnostic cancer drugs will be tied to the use of real-world data and new clinical trial formats.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.